Cartesian Therapeutics (RNAC) Long-Term Investments (2015 - 2025)

Cartesian Therapeutics (RNAC) has 11 years of Long-Term Investments data on file, last reported at $2.0 million in Q3 2025.

• On a quarterly basis, Long-Term Investments changed 0.0% year-over-year to $2.0 million in Q3 2025; TTM through Sep 2025 was $2.0 million, a 0.0% change from a year earlier, with the FY2024 full-year figure at $2.0 million, changed 0.0% from the prior year.
• Long-Term Investments for Q3 2025 stood at $2.0 million, roughly flat from $2.0 million in the prior quarter.
• Over the last five years, Long-Term Investments for RNAC reached as high as $2.0 million in Q3 2021 and fell as low as $2.0 million in Q3 2021.
• Historically, Long-Term Investments has averaged $2.0 million across 5 years, with a median of $2.0 million in 2021.
• Across the five-year window, Long-Term Investments jumped 45.03% in 2021 and changed 0.0% in 2022, its largest moves.
• Year by year, Long-Term Investments stood at $2.0 million in 2021, then changed by 0.0% to $2.0 million in 2022, then changed by 0.0% to $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then changed by 0.0% to $2.0 million in 2025.
• Per Business Quant data, the three most recent Long-Term Investments figures were $2.0 million in Q3 2025, $2.0 million in Q2 2025, and $2.0 million in Q1 2025.